Abstract
For testing bacterial susceptibility to PD131628, a 5-micrograms disk and the following tentative interpretive criteria may be used: > or = 19 mm for susceptible (MIC, < or = 1.0 micrograms/ml), 16 to 18 mm for intermediate (MIC, 2.0 micrograms/ml), and < or = 15 mm for resistant (MIC, > or = 4.0 micrograms/ml). For standard quality control strains, the following limits are proposed: for Escherichia coli ATCC 25922, zones of 31 to 41 mm or a MIC of 0.002 to 0.016 micrograms/ml; for Pseudomonas aeruginosa ATCC 27853, zones of 26 to 34 mm or a MIC of 0.12 to 0.5 micrograms/ml; for Staphylococcus aureus ATCC 25923, zones of 27 to 33 mm; for Staphylococcus aureus ATCC 29213, a MIC of 0.03 to 0.12 micrograms/ml; and for Enterococcus faecalis ATCC 29212, a MIC of 0.12 to 0.5 micrograms/ml.
Full Text
The Full Text of this article is available as a PDF (183.6 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Barrett M. S., Jones R. N., Erwin M. E., Johnson D. M., Briggs B. M. Antimicrobial activity evaluations of two new quinolones, PD127391 (CI-960 and AM-1091) and PD131628. Diagn Microbiol Infect Dis. 1991 Sep-Oct;14(5):389–401. doi: 10.1016/0732-8893(91)90066-o. [DOI] [PubMed] [Google Scholar]
- Barry A. L., Fuchs P. C. Antistaphylococcal activity of the fluoroquinolones CI-960, PD 131628, sparfloxacin, ofloxacin and ciprofloxacin. Eur J Clin Microbiol Infect Dis. 1991 Mar;10(3):168–171. doi: 10.1007/BF01964451. [DOI] [PubMed] [Google Scholar]
- Barry A. L., Fuchs P. C., Citron D. M., Allen S. D., Wexler H. M. Methods for testing the susceptibility of anaerobic bacteria to two fluoroquinolone compounds, PD 131628 and clinafloxacin. J Antimicrob Chemother. 1993 Jun;31(6):893–900. doi: 10.1093/jac/31.6.893. [DOI] [PubMed] [Google Scholar]
- Cohen M. A., Huband M. D., Mailloux G. B., Yoder S. L., Roland G. E., Domagala J. M., Heifetz C. L. In vitro antibacterial activities of PD 131628, a new 1,8-naphthyridine anti-infective agent. Antimicrob Agents Chemother. 1991 Jan;35(1):141–146. doi: 10.1128/aac.35.1.141. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Cooper M. A., Andrews J. M., Wise R. In-vitro activity of PD 131628, a new quinolone antimicrobial agent. J Antimicrob Chemother. 1992 May;29(5):519–527. doi: 10.1093/jac/29.5.519. [DOI] [PubMed] [Google Scholar]
- Ford A. S., Baltch A. L., Smith R. P., Ritz W. In-vitro susceptibilities of Pseudomonas aeruginosa and Pseudomonas spp. to the new fluoroquinolones clinafloxacin and PD 131628 and nine other antimicrobial agents. J Antimicrob Chemother. 1993 Apr;31(4):523–532. doi: 10.1093/jac/31.4.523. [DOI] [PubMed] [Google Scholar]
- Fuchs P. C., Barry A. L., Pfaller M. A., Allen S. D., Gerlach E. H. Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates. Antimicrob Agents Chemother. 1991 Apr;35(4):764–766. doi: 10.1128/aac.35.4.764. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fuchs P. C., Barry A. L., Pfaller M. A. Antibacterial activity of PD 131628 and proposed disc diffusion susceptibility test criteria. J Antimicrob Chemother. 1994 Jun;33(6):1147–1154. doi: 10.1093/jac/33.6.1147. [DOI] [PubMed] [Google Scholar]
- Gavan T. L., Jones R. N., Barry A. L., Fuchs P. C., Gerlach E. H., Matsen J. M., Reller L. B., Thornsberry C., Thrupp L. D. Quality control limits for ampicillin, carbenicillin, mezlocillin, and piperacillin disk diffusion susceptibility tests: a collaborative study. J Clin Microbiol. 1981 Jul;14(1):67–72. doi: 10.1128/jcm.14.1.67-72.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lewin C. S. Antibacterial activity of a 1,8-naphthyridine quinolone, PD 131628. J Med Microbiol. 1992 May;36(5):353–357. doi: 10.1099/00222615-36-5-353. [DOI] [PubMed] [Google Scholar]